Heron Therapeutics Stock News

Cortexyme and Heron Therapeutics are two of the most heavily shorted biopharma stocks right now.

(RTTNews) - Heron Therapeutics, Inc. (HRTX) said the FDA has approved its supplemental New Drug Application for ZYNRELEF extended-release solution to significantly expand the indication. ZYNRELEF is now indicated in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after foot and ankle,

The FDA has approved Heron Therapeutics Inc's (NASDAQ: HRTX) supplemental application for Zynrelef (bupivacaine and meloxicam) extended-release solution to expand the indication.  Zynrelef is now

The Global Chemotheraphy-induced Nausea and Vomitting Treatment Market report offers a comprehensive evaluation of the market. It does give in-depth analysis via qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been

Heron Therapeutics Inc (HRTX) shares closed today at 1.3% above its 52 week low of $9.03, giving the company a market cap of $932M. The stock is currently down 56.8% year-to-date, down 49.1% over the past 12 months, and down 38.0% over the past five years. This week, the Dow Jones Industrial Average fell 1.4%, and the S&P 500 fell 0.6%. Trading Activity Trading volume this week was 10.3% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.9. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 1092.1% The company's stock price performance over the past 12 months lags the peer average by -1507.4% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Heron Therapeutics Inc. (NASDAQ:HRTX) has a beta value of 1.33 and has seen 1.96 million shares traded in the last trading session. The company, currently valued at $996.90M, closed the last trade at $9.41 per share which meant it lost -$0.36 on the day or -3.68% during that session. The HRTX stock price is -138.04% Heron Therapeutics Inc. (NASDAQ: HRTX) Disappointed Wall Street By Losing -3.68% Read More »

Price T Rowe Associates Inc. MD lessened its position in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) by 11.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 50,595 shares of the biotechnology companys stock after selling 6,826 shares during the []

Equities analysts forecast that Heron Therapeutics, Inc. (NASDAQ:HRTX) will report $26.12 million in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Heron Therapeutics earnings, with the lowest sales estimate coming in at $24.00 million and the highest estimate coming in at $28.37 million. Heron Therapeutics reported []

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Heron Therapeutics (NASDAQ:HRTX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, valuation and profitability. Valuation & Earnings This table compares Alnylam Pharmaceuticals and Heron Therapeutics top-line revenue, earnings per share []

Credit Suisse AG lifted its holdings in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) by 26.5% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 82,587 shares of the biotechnology companys stock after buying an additional 17,316 shares during the period. Credit Suisse []

Food and drug administration (fda) for htx-019 (aprepitant) injectable emulsion for the prevention of postoperative nausea and vomiting (ponv) in adults. The post Heron Therapeutics Inc (HRTX): Price Now Near $10.55; Daily Chart Shows Downtrend on 100 Day Basis appeared first on ETF Daily News .

Heron Therapeutics Inc. (NASDAQ:HRTX) price on Wednesday, November 17, fall -4.18% below its previous days close as a downside momentum from buyers pushed the stocks value to $10.77. A look at the stocks price movement, the close in the last trading session was $11.24, moving within a range at $10.695 and $11.20. The beta value Heron Therapeutics Inc. (HRTX): At $10.77, Its Worth Your Attention Read More »

In the last trading session, 1.2 million Heron Therapeutics Inc. (NASDAQ:HRTX) shares changed hands as the companys beta touched 1.33. With the companys per share price at $11.24 changed hands at $0.31 or 2.84% during last session, the market valuation stood at $1.13B. HRTXs last price was a discount, traded about -99.29% off its 52-week Is Heron Therapeutics Inc. (NASDAQ: HRTX) Stock Set To Rise More? Read More »

Analysts forecast that Heron Therapeutics, Inc. (NASDAQ:HRTX) will report sales of $26.68 million for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Heron Therapeutics earnings. The lowest sales estimate is $24.00 million and the highest is $30.03 million. Heron Therapeutics reported sales of $20.61 million in the same quarter last []